Business Context and Reporting Period
Company: TNF Pharmaceuticals, Inc. (TNFA)
Filing Type: Form 8-K (Current Report)
Date of Report: August 28, 2025 (Earliest event reported)
Reporting Period: Events occurring between August 28, 2025, and September 2, 2025.
The filing details a significant capital raise, a strategic acquisition, a reverse stock split, and changes in corporate governance. The company is a Delaware corporation listed on The Nasdaq Capital Market.
Key Financial Metrics and Capital Structure
Private Placement (Series H Preferred Stock):
- Gross Proceeds: Expected $7,000,000.
- Securities Issued: 7,000 shares of Series H Convertible Preferred Stock (stated value $1,000/share) and warrants to purchase 1,400,000 shares of Common Stock.
- Conversion Terms: Initial conversion price of $5.00 per share (subject to full ratchet adjustment).
- Dividends: 7% per annum, compounded monthly, payable in cash. Increases to 15% per annum upon a "Triggering Event."
- Use of Proceeds: General corporate purposes and working capital.
Acquisition (LPU Holdings LLC):
- Consideration: Issuance of Series I Convertible Preferred Stock convertible into 747,362 shares of Common Stock (initial conversion price $0.001).
- Contingent Consideration: Additional cash, stock, and warrants based on milestones, including future equity offerings.
- License Fees: Up to $8,500,000 in non-recurring engineering fees to LightSolver Ltd. plus a one-time cash payment equal to the greater of 25% of Private Placement proceeds or $1,500,000.
Debt and Liquidity:
- Existing Debt: Maturity dates for Series F and Series F-1 Preferred Stock extended to March 2, 2027; amortization payments removed.
- Liquidity: The filing does not provide current cash balances or liquidity metrics, only the expected inflow from the private placement.
Material Changes Versus Prior Period
- Capitalization: Implementation of a 1-for-100 reverse stock split effective August 29, 2025. Authorized shares remain 1,250,000,000.
- Debt Restructuring: Extension of maturity for Series F and F-1 Preferred Stock and removal of amortization obligations.
- Strategic Pivot: Acquisition of LPU Holdings LLC to enter the cryptocurrency mining hardware sector via an exclusive license from LightSolver Ltd.
- Contract Termination: Termination of the Master Service and Technology Agreement with Prevail InfoWorks, Inc. regarding Phase 2 clinical study services for sarcopenia/frailty.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook:
- The company intends to use proceeds for working capital and general corporate purposes.
- Stockholder approval is required for the issuance of shares exceeding 19.99% of outstanding common stock (Nasdaq listing standards). A meeting is scheduled no later than November 16, 2025, for the Private Placement and 60 days post-closing for the Acquisition.
Risks and Contingencies:
- Registration Rights: The company must file resale registration statements within 15 days (Private Placement) and 30 days (Acquisition) of closing. Failure to do so triggers liquidated damages.
- Triggering Events: Failure to file registration statements or pay dividends may trigger a 15% dividend rate and redemption rights for Series H holders.
- Beneficial Ownership Limits: Conversion and exercise of warrants are subject to beneficial ownership limitations until stockholder approval is obtained.
- Financial Advisor Fees: Engagement of Palladium Capital Group involves a $15,000 monthly retainer and issuance of 15,433 shares of common stock.
Unusual Items:
- Executive Changes: Mitchell Glass resigned as President but remains Chief Medical Officer and Board member. Joshua Silverman appointed Executive Chairman. Jude Uzonwanne resigned from the Board.
- Related Party Transaction: PharmaCyte Biotech, Inc. (affiliated with Executive Chairman Joshua Silverman) purchased $3,000,000 of the Series H Preferred Stock.
Investor Verification Checklist
- Verify the closing date of the Private Placement and Acquisition (expected September 4, 2025) and confirmation of fund receipt.
- Confirm the filing and effectiveness of the resale registration statements for the Series H and Series I securities to avoid liquidated damages.
- Monitor the schedule for the stockholder meeting required to approve the issuance of shares exceeding the 19.99% Nasdaq threshold.
- Review the specific terms of the "Triggering Events" in the Series H Certificate of Designations that could accelerate dividend rates to 15%.
- Assess the financial impact of the $8.5 million potential engineering fees and the one-time payment to LightSolver Ltd. against the $7 million gross proceeds.
- Confirm the status of the terminated clinical study with Prevail InfoWorks and any associated costs or liabilities.